Drug intelligence / Profile preview

AV-151

Development stage: Phase 1
Lead developer: Institute for Neurodegenerative Disorders
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Bolus Injection

Overview

AV-151 is a compound investigated as a potential imaging biomarker for beta-amyloid protein deposition in the brain. Specifically, the Iodine-123 labeled version, [123I] AV-151 (also referred to as 123-I AV51), is used in conjunction with single photon emission computed tomography (SPECT) to detect beta-amyloid burden in subjects with Alzheimer's disease and healthy controls. It is designed to assess the dynamic uptake and washout of the radioligand and to characterize its blood metabolites. The Institute for Neurodegenerative Disorders is the lead sponsor for its development.

Other names: [123I] AV-151123-I AV51

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on AV-151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV-151.

Explore the full profile